Stonebrook Private Inc. Sells 8,844 Shares of AbbVie Inc. $ABBV

Stonebrook Private Inc. lessened its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 49.4% during the 4th quarter, HoldingsChannel reports. The firm owned 9,044 shares of the company’s stock after selling 8,844 shares during the period. Stonebrook Private Inc.’s holdings in AbbVie were worth $2,066,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Chelsea Counsel Co. bought a new stake in AbbVie in the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie during the 4th quarter worth approximately $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie during the 3rd quarter worth approximately $31,000. Legacy Wealth Managment LLC ID increased its position in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after purchasing an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC increased its holdings in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie presented new data across its blood cancer portfolio at EHA 2026, with multiple oral presentations reinforcing progress in its oncology pipeline and long-term research efforts. AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
• Positive Sentiment: AbbVie has also been featured in “final trades” and “buy/hold” style commentary, suggesting traders remain constructive on the stock after its recent run and improved guidance outlook. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Neutral Sentiment: Investors are also watching articles that frame AbbVie as an undervalued dividend-growth name, which supports the bull case but does not bring new company-specific news. Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
• Negative Sentiment: AbbVie terminated its deal with I-Mab to develop a cancer drug, a setback that could be viewed as a pipeline/partnership disappointment even if the financial impact appears limited for now. AbbVie terminates deal with I-Mab to develop cancer drug

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of recent analyst reports. Canaccord Genuity Group boosted their target price on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. William Blair restated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Piper Sandler upped their target price on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Trading Up 1.0%

Shares of ABBV stock opened at $225.25 on Wednesday. The stock has a market cap of $397.97 billion, a price-to-earnings ratio of 110.96, a PEG ratio of 0.68 and a beta of 0.32. The stock has a 50-day moving average of $210.40 and a 200-day moving average of $219.12. AbbVie Inc. has a 1-year low of $181.73 and a 1-year high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. During the same quarter last year, the firm posted $2.46 earnings per share. The firm’s revenue was up 12.4% on a year-over-year basis. Sell-side analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.